California on Wednesday became the fifth state—and by far the largest—to win approval of a CMS demonstration project that will put beneficiaries dually eligible for Medicare and Medicaid into managed-care plans.
The CMS drew heavy criticism last year for the scope and pace of the Financial Alignment Initiative, which stems for the Patient Protection and Affordable Care Act and seeks to find a way to rein in costs for a disproportionately expensive population of patients.
Dual eligibles are among the highest-cost users of healthcare services in California's Medicaid program, Medi-Cal, accounting for 25% of its spending, according to DHCS.
Read the full story here: http://bit.ly/171PWdr
Source: Modern Healthcare
The agreement between the California Department of Health Care Services and the CMS (PDF) will provide a single, capitated monthly payment for providing services for about 456,000 dual-eligible enrollees, beginning in October. While that figure is significant, it is about half as much as Democratic Gov. Jerry Brown requested in early 2012.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Homelessness Compounds Hospital Stay Challenges: Study Reveals Prolonged Discharge Struggles
March 28th 2024In this investigation, outcomes of interest were morbidity rate and length of hospital stay or a traumatic injury among a homeless population, and whether age and/or injury severity had an influence on that relationship—with implications for improving the discharge process for these patients.
Read More
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More